Abstract The convergence of biotechnology innovation and decentralized finance represents a pivotal moment in corporate strategy, particularly as firms navigate volatile capital markets and geopolitical uncertainties in 2025. This analysis addresses the core question of why an Israeli clinical-stage biopharmaceutical company, Enlivex Therapeutics Ltd. (NASDAQ: ENLV), headquartered in Ness Ziona, would allocate $212 million from … Leggi tutto Enlivex, with Matteo Renzi on Board, Launches First RAIN-Backed Treasury to Power Israeli Biotech via Prediction Markets